Fourth Annual
Next Generation Dx Summit
Moving Assays to the Clinic
August 21-23, 2012
Hyatt Regency on Capitol Hill
Washington, DC

Final Agenda

Keynote Discussion:
Regulation of LDTs and RUOs
Franklin R. Cockerill, III, M.D., Mayo Medical Laboratories and Mayo Collaborative Services, Inc.

Alberto Gutierrez, Ph.D., Office of in vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration

Keynote Session:
Position of IVDs on Regulatory Issues
Alan Mertz, American Clinical Laboratory Association (ACLA)

Diagnostic Manufacturers: Key Regulatory Issues
Andrew C. Fish, Executive Director, AdvaMedDx

The Next Generation Dx Summit brings together all of the major players in the evolving areas of diagnostics.

AUGUST 21-22
- Enabling Point-of-Care Diagnostics
- Emerging Molecular Markers of Cancer
- Mass Spectrometry in Diagnostics of Infectious Disease
- Regulatory Compliance in Drug-Diagnostic Co-Development

AUGUST 22-23
- Molecular Diagnostics for Infectious Disease
- Companion Diagnostics
- Commercialization of Molecular Diagnostics

AUGUST 19
- Emerging Diagnostic Partnering and Investment Forum

Organized by
Cambridge Healthtech Institute

NextGenerationDx.com
Event-at-a-Glance

<table>
<thead>
<tr>
<th>Sunday</th>
<th>Emerging Diagnostic Partnering and Investment Forum*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>Pre-Conference Short Courses*</td>
</tr>
<tr>
<td>Tuesday AM</td>
<td>Enabling Point-of-Care Diagnostics</td>
</tr>
<tr>
<td>Tuesday PM</td>
<td>Enabling Point-of-Care Diagnostics</td>
</tr>
<tr>
<td>Wednesday AM</td>
<td>Enabling Point-of-Care Diagnostics</td>
</tr>
<tr>
<td>Wednesday PM</td>
<td>Molecular Diagnostics for Infectious Disease</td>
</tr>
<tr>
<td>Thursday AM</td>
<td>Molecular Diagnostics for Infectious Disease</td>
</tr>
<tr>
<td>Thursday PM</td>
<td>Molecular Diagnostics for Infectious Disease</td>
</tr>
</tbody>
</table>

* Separate Registration Required

About the Summit

Technological advances in next generation diagnostics are driving growth and innovation in healthcare. Rapid and precise diagnosis is essential for personalized medicine and will change the way value is assessed and compensated in the healthcare system. This meeting offers a comprehensive view of the changing landscape of diagnostics and brings together the key players in the field.

The Next Generation Dx Summit is designed to bring together all of the major players in the evolving areas of diagnostics. This year, we have assembled an impressive faculty of speakers from industry, government, and leading academic institutions. This meeting will showcase improvements in technology research and development with an emphasis on applications in the clinic and commercialization. Plan to hear what the industry leaders are saying about future market opportunities and network with your peers this August 21-23 in Washington, DC.

“The meeting was excellent, one of the best I have attended, and the standard of talks matched to the schedule across the board.”
Vice President, Diagnostics, GlaxoSmithKline

“The Next Generation Dx Summit is the Conference to attend if you seek not only to learn about cutting edge diagnostics but to meet the people who develop and implement them.”
R&D Consultant, Randox Laboratories

CORPORATE SPONSORS

2 | Next Generation Dx Summit
NextGenerationDx.com
Short Courses*

**Morning Short Courses**  
Monday, August 20 | 9:00 am-12:00 pm

**SC1 Micro- and Nanofluidics in Diagnostics and Life Sciences: Technologies, Applications and Markets**  
Holger Becker, Ph.D., CSO, microfluidic ChipShop GmbH
- Understand the basic physical principles and scaling laws governing miniaturization
- Identify the suitable material for a given microfluidic application
- Obtain an overview on the basic technologies available for the microfabrication of glass, silicon and polymer materials
- Understand the development strategies for integrated microfluidic devices
- Learn application examples of microfluidic devices in a wide range of disciplines
- Understand the current state of the markets and obstacles in the commercialization process

**SC2 Smarter Studies: Boosting Your Omics and Biomarker Projects through an Efficient and Rigorous Study Design**  
Jürgen von Frese, Ph.D., Managing Director, Data Analysis Solutions DA-SOL GmbH
- Why study design is decisive for success
- Common pitfalls and how to avoid them
- Planning your study from start to finish
- Getting the optimum out of your budget
- Ensuring validity
- Regulatory aspects

**SC3 Differentiating Lateral Flow Products from the Competition Based on Performance and Design**  
Brendan O’Farrell, Ph.D., President, Diagnostic Consulting Network
- Understand the issues in the generation of high sensitivity, highly reproducible lateral flow assays as well as key ways to control variability
- Learn about choices in labels and the advantages and disadvantages of each
- Learn about reagent selection criteria and methods for optimizing rapid assay performance
- Understand the options in reader design and learn about the key manufacturers and products available as well as options in the design of multiplexed assays
- Understand the design elements that go into a user friendly, single step lateral flow assay system
- Learn the process for the design and development of intuitive point-of-care devices
- Understand typical timelines, costs and outputs of OEM device and assay development programs for complete rapid assay systems
- See the unveiling of a new technology for the generation of intuitive, easy to read results in lateral flow assays

**SC4 Latest Advances in Molecular Pathology**  
Jack H. Lisy, M.D., Ph.D., Chief, Pathology & Laboratory Medicine, VA Medical Center, Washington, D.C.
Karen E. Weck, M.D., Professor and Director of the Molecular Genetics Laboratory, University of North Carolina School of Medicine
Jennifer J.D. Morissette, Ph.D., Adjunct Assistant Professor, Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine; Clinical Director, Center for Personalized Diagnostics, Hospital of the University of Pennsylvania
- Moving more effective markers to the clinic

**SC5 Applications of Detection Theory in Diagnostics**  
John C. Carrano, Ph.D., President, Carrano Consulting, LLC
- The Dichotomous Test
- Analysis and definition of FP, FN, CP, CN as well as sensitivity, specificity, and LOD
- Construction of the Receiver Operating Characteristic
- ROC Curve Trends and Interpretation
- Negative and positive predictive values
- Detection theory and measurements
- Applications of ROC curves in sensing and diagnostics
- Mathematical principle of cost-benefit analysis and application to product choice
- Principles of decision tree analysis as well as construction, interpretation and practical applications
- The "spider" chart and systems level analysis

**SC6 Next Generation Sequencing in Molecular Pathology: Challenges and Applications**  
Shashikant Kulkami, Ph.D., Head, Clinical Genomics & Medical Director, Cytogenomics and Molecular Pathology, Pathology, Pediatrics and Genetics, Washington University School of Medicine
- Jamie Platt, Ph.D., Scientific Director, Advanced Sequencing, Quest Diagnostics Nichols Institute

**SC7 Introducing Mass Spectrometry into a Clinical Laboratory**  
Michael E. Hodsdon, M.D., Ph.D., Associate Professor of Laboratory Medicine and Pharmacology, Yale University
David R. Peaper, M.D., Ph.D., Department of Laboratory Medicine, Yale University
- Modular view of chromatographic methods and modern mass spectrometer
- Practical aspects of introducing mass spectrometry into a clinical laboratory
- Development and validation of mass spectrometric methods
- Maintaining regulatory compliance (e.g. CAP) with your mass spectrometer

**SC8 Cardiovascular Biomarkers: Clinical Impact and Crossover Applications**  
Allan S. Jaffe, M.D., Chair, Division of Core Clinical Laboratory Services, Department of Laboratory Medicine and Pathology, Mayo Clinic
Peter Kuhn, Ph.D., Associate Processor, Cell Biology, The Scripps Research Institute
Anand Rohatgi, M.D., MSCS, FACC, Assistant Professor, Preventive Cardiology, UT Southwestern Medical Center
Additional Instructors to be Announced
- The relation between cancer and cardiovascular disease
- Initiatives in cardiology that aid in cancer research
- Improved diagnostic information with the use of high sensitivity cardiac troponin
- Moving more effective markers to the clinic

**SC9 The Future of Point-of-Care Diagnostics**  
Keith F. Batchelder, M.D., CEO, Genomic Healthcare Strategies
- How will partnering evolve?
- What strategies make sense for Dx and POC companies?
- Where will the new markets be?
- What strategies make sense for Dx and POC companies?
- How will partnering evolve?

**SC10 Deal Making in Companion Diagnostics: CDx Deals Today and Tomorrow**  
Jorge Leon, Ph.D., President, Leomics Associates, Inc.
Additional instructors to be Announced
- Deals between pharma and diagnostics in discovery, development and commercialization
  - Needs from pharma
  - Deliverables from diagnostics and the desired outcomes
  - Average costs and financial structures
- Ingredients necessary to create the ideal type of pharma/diagnostics deals in order to increase the value for the diagnostic partners and to maximize the outcomes for the pharma partners.

**SC11 The Future of Personalized Diagnostics**  
Roxana C. Perrotti, Ph.D., Chief, Research Laboratory, Mayo Clinic
- How will the technology continue to evolve?
- What will the future hold for personalized diagnostics?
- What are the ethical, legal and social implications of personalized diagnostics?
- What are the regulatory hurdles that need to be overcome?

**SC12 The Future of Cytogenomic Diagnostics**  
M. Kyle Bronson, Ph.D., Director of Research, Cytofex, Inc.
- What are the future trends in cytogenomic diagnostics?
- What are the challenges and opportunities for cytogenomic diagnostics in the future?
- What are the future applications of cytogenomic diagnostics?
Focusing on the Right Partners

McClernon LLC
Jorge Leon, Ph.D.,
President,
Development, Lilly Corporate Center
Director, New
Brian T. Edmonds, Ph.D.,
4 | Next Generation Dx Summit
NextGenerationDx.com

networking, partnering and investment exploration discussions.

The pace of innovation continues to accelerate within the field of molecular diagnostics, making the right strategic partnerships critical to the development of promising new technologies and applications. CHI’s Emerging Diagnostic Partnering & Investment Forum will bring together exciting early stage companies with decision makers representing pharma, larger biotechs, and VCs, providing an efficient opportunity to learn about emerging technologies and engage in networking, partnering and investment exploration discussions.

**SUNDAY, AUGUST 19**

**PRESENTING COMPANIES:**

**Daktari Diagnostics**
Daktari has developed novel microfluidic control systems that enable separation of target analytes without sample preparation. Users introduce a drop of blood, and the handheld instrument completes the assay. A novel electrochemical sensing method greatly simplifies target detection, eliminating the need for optics or optical reagents.

**Adarza**
Adarza has developed a proprietary technology and product platform for biological detection that enables higher levels of differentiating analytical and workflow performance. Arrayed Imaging Reflectometry offers a unique combination of sensitivity and highly multiplexed detection on inexpensive microarray substrates.

**AquaBioChip**
AquaBioChip's technology integrates genomic information, isothermal amplification, simple optics for real time monitoring, microfluidics, and consumer electronics in a simplified package that works for many applications (genetic diagnostics related to clinical, food, water, and plant pathogens) under field conditions.

**Aviana**
Aviana is developing a unique biosensor which is entirely electronic, translating a specific biological action directly into an electronic signal without the need for any other intervening technologies like optical or magnetic systems, which, in most systems, are needed to amplify and create bulky and complex systems.

**Biocartis**
Biocartis is engaged in the development of novel diagnostics platforms for low to highly multiplexed detection of molecular-based biomarkers. We are focused on the delivery of versatile and compact platforms that will make the testing of molecular diagnostics easier to perform in a wider range of healthcare settings.

**iCubate**
iCubate has developed the arm-PCR (amplicon rescued multiplex PCR), a fully integrated system that performs DNA/RNA extraction, amplification and detection, multiplexed, automated, and in a closed cassette. We integrated arm-PCR and PPI (polymerase preference index) algorithm into a software that is free to developers.

**IVDiagnostics, Inc.**
IVDiagnostics is focused on molecular diagnostics for blood borne diseases, with an initial field of interest is metastatic cancer. The IVDx system utilizes in vivo technology. We can scan one liter of a patient’s blood without taking blood. Our molecular diagnostic platform uses aptamers applied to captured CTCs.

**MBio Diagnostics**
MBio Diagnostics is developing a platform for comprehensive diagnosis at the point of care by integrating panels of measurements in an easy-to-use system, for decentralized testing, from health clinics to the home. Initial products are infectious disease panels with attractive global markets. An elegantly simple biosensor enables highly sensitive multiplex rapid testing, with low cost to manufacture.

**Xagenic**
Xagenic is a venture-backed startup company founded in 2010 to commercialize a chip-based platform for molecular analysis with unprecedented sensitivity, speed and simplicity. Xagenic’s technology is highly versatile and has been validated against a variety of cell and sample types.

**FEATURED PANEL DISCUSSION:**

Leveraging Strategic Alliances and Partnerships to Bring Diagnostics to the Market
Moderated by Katherine Tynan, Ph.D., Business Development & Strategic Consulting for Diagnostics Companies, Tynan Consulting LLC

View the complete agenda and detailed presentation information on our website: www.nextgenerationdx.com/Dx-Partnering

* Separate Registration Required

**PROGRAM ADVISORY BOARD**

**Brian T. Edmonds, Ph.D.,** Director, New Technologies, Global External Research & Development, Lilly Corporate Center

**Jorge Leon, Ph.D.,** President, Leomics Consulting

**Daniel R. McClemon,** McClemon LLC

**Charlie Raffin,** Consultant

**David Rubin, Ph.D.,** Senior Director, Global Health Innovation Group, Merck & Co.

**Ali Tinazli,** Director, Business Development & Sales, BioSciences - North America, Sony DADC

**Katherine Tynan, Ph.D.,** Business Development & Strategic Consulting for Diagnostics Companies, Tynan Consulting LLC

**Penny Wilson, Ph.D.,** Innovation Platform Leader, Stratified Medicine Technology Strategy Board
TUESDAY, AUGUST 21

7:30 am Registration and Morning Coffee

»KEYNOTE SESSION: MAKING THE CASE FOR POINT-OF-CARE TESTING

8:30 Chairperson’s Opening Remarks
Penny Wilson, Ph.D., Innovation Platform Leader, Stratified Medicine Technology Strategy Board

8:40 Revolutionary Point-of-Care (POC) Diagnostic Technologies to Improve the Prevention, Control and Treatment of Infectious Diseases
Michel G. Bergeron, O. O., M.D., FRCPC, Director and Founder, Centre de Recherche en Infectiologie de l’Université Laval

In 2012, it still takes 2-2 days to identify most microbes responsible for infectious diseases. This lack of rapid diagnostics has led to empirical therapy, the overuse of antibiotics, and a dangerous increase in antibiotic resistance, hospital-acquired infections (HAI), and in deaths. Combining genomics, microfluidics, miniaturized optics, and microcentripetal forces, we have developed a simple “lab-on-a-chip” device on a compact disc (CD) platform that reads DNA of microbes and which allows the diagnosis of up to 8 infections simultaneously at POC in real time.

9:10 HIV Viral Load Testing from Centralized Laboratories to POC Options
Lesley Scott, Ph.D., Professor, Molecular Medicine and Hematology, University of Witwatersrand

9:40 POC: The Search for the Holy Grail Continues
Harry Glorikian, Founder and Managing Partner, Scientia Advisors LLC

There is significant room for improvement in POC diagnostics. The sensitivity of lateral flow strips is unsatisfactory and immunoassays are insufficient for critical care/emergency situations. Developing markets may expedite approval, but this would be limited to specific geographies and conditions. The Holy Grail remains elusive: Rapid antigen level TaT + MDx accuracy, multiplexing capabilities, integration to laboratory information management systems (LIMS), reasonable cost, and easy-to-use.

10:10 Coffee Break

Evidence Required for Approval

10:55 Chairperson’s Remarks
Sheldon Campbell, M.D. Ph.D. F.C.A.P, Department of Laboratory Medicine, Yale University School of Medicine

11:00 Infectious Disease Tests and Point-of-Care, an FDA Perspective
Francisco Martinez-Murillo, Ph.D., Staff Fellow, FDA CDRH

This talk will cover current FDA approaches to regulating rapid tests and testing algorithms based on rapid tests, particularly for detection of infectious disease when applied to point-of-care settings.

11:30 Evaluating Evidence for Diagnostic Tests: How Can We Improve Bench to Bedside Process?
Penny Wilson, Ph.D., Innovation Platform Leader, Stratified Medicine Technology Strategy Board

12:00 pm Use of Rapid Care Diagnostic Tests and Point-of-Care Diagnostics by Pharmacists
Michael E. Klepsner, Pharm.D., FCCP Professor of Pharmacy, Ferris State University

Pharmacists are uniquely positioned to identify patients early in the course of disease. The role of these tests and our experiences will be addressed.

12:30 Differentiating Your Lateral Flow Assay; High Sensitivity, Fluorescent Reader Based Assays with Enhanced Functionality
Brendan O’Farrell, Ph.D., President, Diagnostic Consulting Network, Inc.

Attendees will learn about the key features of quantitative, sensitive, fluorescent lateral flow assays and be introduced to a novel method for the generation of highly functional signals in lateral flow, including parallel lines, arrays, letters, numbers or symbols, yielding intuitive, easily interpreted signals, simplified multiplexing, and improved quantification.

12:45 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

2:00 Session Break

Rapid Testing and the New HIV Testing Algorithm

2:15 Chairperson’s Remarks
Christine C. Ginocchio, Ph.D., M.T (ASCP), Hofstra University North Shore-LIJ School of Medicine

2:20 Overview and Impact of POC Testing
Bernard Branson, M.D., Medical Epidemiologist, Division of HIV/AIDS Prevention, Centers for Disease Control & Prevention

POC testing for HIV now plays a substantial role in identifying new HIV infections and facilitating linkage to care. However, with increasing recognition of importance of acute HIV infection in the onward transmission of HIV, CDC has proposed a new diagnostic HIV testing algorithm designed to improve detection of the acute HIV infection, reduce indeterminate test results, and facilitate the correct classification of HIV-2. This new algorithm currently depends on conventional laboratory tests, which might jeopardize some of the benefits associated with point-of-care testing such as improved access for hard to reach populations and reduced turnaround time, which increases receipt of test results. This overview will describe the rationale for the new testing algorithm and the challenges that demand new techniques for POC HIV technology.

2:40 Why Alere Determine HIV-1/2 Ag/Ab Combo First? Advantages of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test as Compared to Ab Only Tests for Screening of HIV Infection at the Point-of-Care
Tomer Kerem, Ph.D., Project Leader, R&D, Orgenics Ltd., a subsidiary of Alere, Inc.

Combined HIV antigen and antibody tests (4th generation) provides earlier detection of HIV infection than that afforded by antibody-only tests (3rd generation), yet are limited to central labs. The Alere Determine® HIV 1/2 Ag/Ab Combo is a novel point of care test bringing 4th generation capabilities to healthcare settings were 3rd generation HIV rapid tests algorithms are the mainstay.

3:00 Geenius™ HIV 1/2 Supplemental Assay: A New Unitary and Innovative Assay for Both Confirmation and Differentiation of HIV-1 and HIV-2 Antibodies in Less Than 30 Minutes
Christopher Bentzen, M.S., RAC, Regulatory Affairs Manager, Bio-Rad Laboratories

The Geenius™ HIV 1/2 Supplemental Assay is a single-use immunochromatographic test for the confirmation and differentiation of individual antibodies to HIV-1 (Group M & O) and HIV-2 in finger stick whole blood, venous whole blood, serum, and plasma samples. It employs HIV-1 and HIV-2 recombinant and/or peptide based antigens bound to a membrane and utilizes colloidal gold to develop a purple line for HIV-1/2 antigens and a control. The assay uses an innovative Geenius® Reader and associated Geenius software for result interpretation and reporting. Bar coding of patient samples and Geenius cartridges allow for full traceability of the system.
3:20 A New Test for the Determination of HIV 1/2 Viral Load at the Point-of-Care
Eugen Ermantraut, Managing Director, Alere Technologies GmbH
Quantitative determination of viral load using nucleic acid amplification techniques is considered to be the most accurate prognostic marker for HIV infection. Point-of-Care (POC) Viral Load test availability is expected to have a significant positive effect on treatment efficacy and health outcome of HIV patients. At the POC, and in particular in a pediatric context, large samples of plasma are difficult to obtain, whereas small amounts of whole blood collected by finger stick or heel prick sampling techniques are readily available. We have developed a fully integrated POC HIV-1/2 Viral Load test that operates using a battery powered instrument, which requires no operator handling starting from whole blood and have characterized its performance. The test targets un-spliced RNA of HIV-1 and HIV-2. All process steps including sample application, lysis, RNA capture, reverse transcription, target amplification and multiplexed real time detection on an integrated probe array have been accommodated on the disposable test cartridge. Commercially available reference material and the WHO standards were used to calibrate the test and to determine the lower limit of detection, linearity and dynamic range. Specificity and sensitivity of the test have been determined using blood samples from donors with confirmed HIV-infection and from confirmed HIV negative volunteers. As a reference, plasma viral load was measured on the COBAS Ampliprep/COBAS Taqman system. The test provides a quantitative viral load for HIV-1 and HIV-2 in less than one hour for a sample of 25μL of whole blood.

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing

9:30 Sponsored Presentation (Opportunity Available)

10:00 Coffee Break in the Exhibit Hall with Poster Viewing

Health Economics

10:25 Chairperson’s Remarks
Shuqi Chen, Ph.D., CEO, iQuum, Inc.

10:30 Health Economics of Point-of-Care Diagnostics – What is the Price of POC Tests?
Ala Szczepura, D.Phil., Professor of Health Services Research, Division of Health Sciences, Warwick Medical School
This talk will consider economic issues associated with new point-of-care tests. It will use POC tests for infection detection as an example e.g. sepsis, tuberculosis, sexually transmitted infections and antimicrobial resistance. These four clinical/disease areas have recently been prioritised by the UK Department of Health and they form a major investment in innovation commissioned by the Technology Strategy Board.

11:00 POCT in the Hospital Setting: New Technologies, Clinical Utility, and Financial Considerations
Gyorgy Abel, M.D., Ph.D., Director, Molecular Diagnostics/Immunology/ Clinical Chemistry, Department of Laboratory Medicine, Lahey Clinic Medical Center
POCT is generally more expensive and more difficult to manage than tests on high-throughput central lab platforms. POCT can offer shorter turnaround times and convenience, and might impact outcomes. Implementing POCT programs requires careful analysis, including comparison of the quality of the results, potential errors in sample handling and reporting of the results, the additional physician, nurse, and medical technologist time, information technology, maintenance, quality control, regulatory requirements, and costs. The talk reviews the economy of POCT in the context of recent technological advancements and the changing healthcare environment, and offers real life examples of clinical chemistry and molecular diagnostics applications.

13:00 Transition to Plenary Session

11:50 PLENARY KEYNOTE DISCUSSION
Regulation of LDTs and RUOs
Alberto Gutierrez, Ph.D., Deputy Director, Office of in vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration
Moderated by: Franklin R. Cockerill, III, M.D., Ann and Leo Markin Professor of Microbiology & Medicine; Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine; President and CEO, Mayo Medical Laboratories and Mayo Collaborative Services, Inc.

12:45 pm Enjoy Lunch On Your Own

1:45 Views of the Laboratory Industry on Regulatory Issues
Alan Mertz, President, American Clinical Laboratory Association (ACLA)

2:10 Views of Diagnostics Manufacturers on Regulatory Issues
Andrew C. Fish, Executive Director, AdvaMedDx

2:30 Close of Enabling Point-of-Care Diagnostics

WEDNESDAY, AUGUST 22

7:30 am Problem Solving Breakout Discussions with Continental Breakfast

Sources of Error in POC Devices

8:30 PANEL DISCUSSION: Sources of Error in POC Devices: Where Do Things Go Wrong in the Real World?
Moderator: James H. Nichols, Ph.D., DABCC, FACB, Professor of Pathology, Tufts University School of Medicine; Medical Director, Clinical Chemistry, Baystate Health Panels: Sheldon Campbell, M.D., Ph.D., F.C.A.P, Department of Laboratory Medicine, Yale University School of Medicine; Pathology and Laboratory Medicine, VA Connecticut
Christine C. Ginocchio, Ph.D., M.T. (ASCP), Chief, Division of Infectious Disease Diagnostics, Department of Pathology and Laboratory Medicine, Professor, Hofstra University North Shore-LIJ School of Medicine
7:30 am Registration and Morning Coffee

**Sequencing for Biomarker Analysis and Discovery**

8:30 Chairperson’s Opening Remarks
Lyle Arnold, Ph.D., CEO, Biocept

8:40 From Assay to Answers to Action: Clinical Implementation of High-Throughput Sequencing for Improved Cancer Care
Oliver Harisimendy, Ph.D., Research Associate, Division of Genomic Medicine, Moores UCSD Cancer Center

9:10 Circulating Tumor Cells and Plasma as Sample Types for Biomarker Analysis
Lyle Arnold, Ph.D., CEO, Biocept

9:40 Advanced Molecular Diagnostics Based on Ultrtrasensitive RNA in situ Hybridization
Yuling Luo, Ph.D., Founder, President & CEO, Advanced Cell Diagnostics, Inc.

9:55 High Sensitivity Detection of Cancer-Associated Mutations in FFPE and FNA Biopsies Using Different PCR Enrichment and NGS Methods
Elizabeth Mambo, Ph.D., Senior Scientist, Technology Development, Asuragen Inc.

11:30 Clinical Application of Next Generation Sequencing for Actionable Mutations in Cancer
Marilyn M. Li, M.D., Professor, Department of Molecular and Human Genetics, Baylor College of Medicine

Mutation detection in cancer has been a challenge due to the mosaic nature of tumor tissues and the genomic heterogeneity of tumor clones. Targeted NGS permits deep sequencing of hundreds of mutations concurrently. The technology allows the detection of multiple clinically actionable mutations at the same time with high sensitivity and specificity. The low input DNA, short turn around time, and low cost of targeted NGS provide huge potential of clinical utility, including diagnostic and therapeutic applications.

12:00 Clinical Applications of Cancer Genomics
John McPherson, Ph.D., Director, Genome Technologies, Ontario Institute for Cancer Research

Next-generation sequencing (NGS) enables deep sequencing of tumour biopsies to reveal the landscape of somatic mutations. Many detected mutations can help guide therapeutic decisions but the functional consequence of others remain to be elucidated. As data are accumulated in conjunction with functional studies and patient outcome new biomarkers can potentially be revealed.

12:30 Towards a Human Clinical Grade Genome - EdgeBio and The Archon Genomics X PRIZE Presented by Medco
Justin Johnson, Director, Bioinformatics, EdgeBio

The Archon Genomics X PRIZE presented by Express Scripts created a “Validation Protocol” that is helping to define for the first time what it means to have a complete and accurate “medical grade” whole human genome sequence. This presentation will describe the Validation protocol in detail.

12:45 Randox Biochip Array Technology: A Revolutionary Step in Multiplex Oncogene Mutation Screening
Robert Wilson, Lead, Molecular Pathology, Northern Health & Social Care Trust

Randox have developed award-winning Biochip Array Technology (BAT) for rapid proteomic, and most recently, genomic diagnostics across a range of human diseases. Utilizing multiplex PCR, spatially tethered specific probes and chemiluminescence detection methods, our innovative array simultaneously identifies 20 mutations across KRAS, BRAF and PIK3CA oncogenes within 3 hours.

1:00 Luncheon Presentation
**NextGen Technology Solutions for Patient Selection and Monitoring**
Jin Li, Ph.D., Research Director, Advanced Diagnostics, MolecularMD Corp.

In the era of personalized medicine, new methodologies enable development of increasingly sensitive clinical assays that provide more comprehensive tumor characterization using minimal tissue or blood samples. Case studies will be presented highlighting NGS and digital PCR as platform solutions for selecting patients for targeted therapies, monitoring therapeutic responses, and detecting emergent drug resistance.

1:15 Lunch Break

2:00 Chairperson’s Remarks
George Netto, M.D., Associate Professor of Pathology, Urology and Oncology, Johns Hopkins University School of Medicine

2:05 The Role of Molecular Markers in the Diagnosis of Non-Small Cell Lung Cancer
Peter B. Illei, M.D., Assistant Professor of Pathology, Johns Hopkins University School of Medicine, Director, Immunopathology Laboratory, The Johns Hopkins Hospital, Baltimore, Maryland

Histology and the presence of driver mutations are predictive of response to systemic therapy. Immunohistochemistry is important for accurately classifying tumors, while molecular studies can identify common driver mutations (i.e.: EGFR mutation, EML4-ALK translocation, k-ras mutation, B-Raf mutation, Her2 mutation) that can be targeted. These analyses should be performed in all adenocarcinomas and other non-squamous non-small cell lung carcinomas.
2:35 Advances in the Development of Clinical Tests Using MALDI-TOF Mass Spectrometry
Heinrich Röder, D.Phil., CTO, Biodesix
The Biodesix mass spectrometry test discovery platform, ProTS, measures protein/peptide expression data reproducibly in a high throughput fashion. This platform has been successfully employed in the development of a commercially available, multivariate test, VeriStrat, developed to help physicians guide treatment in solid epithelial tumors, including NSCLC and SCCHN.

2:50 Human Papillomavirus and Carcinomas of the Head and Neck
Justin A. Bishop, M.D., Assistant Professor of Pathology, Johns Hopkins Bayview Medical Center
This talk will discuss the role of human papillomavirus (HPV) in head and neck cancers. I will briefly touch upon mechanisms of oncogenesis, histopathologic findings, and implications for diagnosis and management.

3:20 Incorporating Next-Gen Sequencing into the Clinical Environment
Anthony P. Shubert, CTO, Predictive Biosciences
We have recently developed a non-invasive assay that uses Next Gen sequencing to detect single mutant molecules of FGFR3 in urine that are indicative of bladder cancer. The superior analytical sensitivity of this assay results in mutation detection in urine that is >90% concordant with that found in tissue. This NGS approach can be applied to other cancer markers and bodily fluids to improve clinical performance and ultimately, patient management.

3:35 Refreshment Break in the Exhibit Hall with Poster Viewing

4:10 Molecular Genetics of Pancreatic Neoplasms: Insights from High-Throughput Sequencing
Laura Wood, M.D., Ph.D., Pathology, Johns Hopkins University School of Medicine
Neoplasms of the pancreas cover a wide clinical spectrum, from benign tumors to the deadliest cancers. Recent large-scale sequencing analyses provided great insights into the unique biology of pancreatic neoplasms, deepening our understanding of tumorigenesis in the pancreas. Moreover, these studies identified several promising targets for the development of novel diagnostics and therapeutics, highlighting the ability of genomic analyses to pinpoint clinically-actionable alterations.

4:40 Renal Cell Carcinoma: Current and Emerging Therapies and Biomarkers
Hans Hammer, M.D., Ph.D., Assistant Professor, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
The treatment paradigm for kidney cancer has changed dramatically over the last decade. Current and emerging therapies and potential biomarkers will be reviewed.

5:10 Wine and Cheese Pairing Welcome Reception in the Exhibit Hall with Poster Viewing

6:10 Close of Day

WEDNESDAY, AUGUST 22

7:30 am Problem Solving Breakout Discussions with Continental Breakfast

Cancer Stem Cell Markers: Proving Their Existence and Understanding Tumor Cell Heterogeneity

8:25 Chairperson’s Opening Remarks

8:30 Cancer Stem Cells: To Believe or Not to Believe
Sunil Badve, Ph.D., Associate Professor, Clarian Pathology Laboratory, Indiana University School of Medicine

9:00 Translating the Cancer Stem Cell Hypothesis from the Lab to the Clinic
William Matsui, M.D., Associate Professor of Oncology, Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (tentative)

9:30 Sponsored Presentation (Opportunity Available)

9:45 Sponsored Presentation (Opportunity Available)

10:00 Coffee Break in Exhibit Hall with Poster Viewing

10:30 Emerging Cancer Stem Cell Biomarkers Based on the “9th Hallmark of Cancer”
James Sherley, M.D., Ph.D., Senior Scientist, Programs in Regenerative Biology and Cancer Biology, Director, Adult Stem Cell Technology Center, Boston Biomedical Research Institute
Carcinogenesis has been attributed to eight cellular alterations highlighted as the “Hallmarks of Cancer.” This representation overlooks a “9th Hallmark of Cancer,” the absolute requirement for originating tissue stem cells to shift from asymmetric self-renewal kinetics to increased symmetric self-renewal kinetics to achieve the cell production rates necessary to form clinically significant tumors. Biomarkers for asymmetric self-renewal are now emerging. Beyond identifying tissue stem cells, these novel biomarkers also have potential to be highly effective for detecting cancer stem cells.

11:00 Tracking Stem Cell Overpopulation during Colon Cancer Development
Bruce Boman, M.D., Thomas Jefferson University Hospital
Recent developments in the identification and isolation of colon cancer stem cells (SC) using SC markers will be discussed. The hypothesis is that the mechanism that links abnormalities at the gene level and abnormalities at the tissue level is stem cell overpopulation. The concept that symmetric cancer stem cell division is a key mechanism that drives tumor growth, and that development of a new generation of therapeutics that target colon cancer SC holds promise for patients with advanced colorectal cancers will also be addressed.

11:30 Transition to Plenary Session

11:50 PLENARY KEYNOTE DISCUSSION
Regulation of LDTs and RUOs
Alberto Gutierrez, Ph.D., Deputy Director, Office of in vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration
Moderated by: Franklin R. Cockerill, III, M.D., Ann and Leo Markin Professor of Microbiology & Medicine; Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine; President and CEO, Mayo Medical Laboratories and Mayo Collaborative Services, Inc.

12:45 pm Enjoy Lunch on Your Own

PLENARY KEYNOTE

1:45 Views of the Laboratory Industry on Regulatory Issues
Alan Mertz, President, American Clinical Laboratory Association (ACLA)

2:10 Views of Diagnostics Manufacturers on Regulatory Issues
Andrew C. Fish, Executive Director, AdvaMedDx

2:30 Close of Emerging Molecular Markers of Cancer Conference
Introducing Mass Spectrometry into a Clinical Laboratory

*Separate registration required, please see page 3 for details

**TUESDAY, AUGUST 21**

1:00 pm Registration

**Applying Mass Spec-Based Methods to Infectious Disease**

**2:15 Chairperson’s Remarks**
Robin Patel, M.D., Chair, Division of Clinical Microbiology, Consultant, Divisions of Clinical Microbiology and Infectious Diseases, Professor of Microbiology and Medicine, College of Medicine, Mayo Clinic

**2:20 Progress and Approaches in Developing Mass Spectrometry-Based Proteomic Assays to Distinguish Clinical Strains of Methicillin-Sensitive and Methicillin-Resistant *Staphylococcus aureus***
Richard R. Drake, Ph.D., Professor and Director, MUSC Proteomics Center, Medical University of South Carolina

The use of MALDI-TOF mass spectrometry to identify bacteria at the genus and species level is becoming standard in many clinical microbiology laboratories. Extending these methods and development of other mass spectrometry-based diagnostics for identification of strain differences within a species, particularly for clinical isolates, remains a challenge. Our group has been focusing on assay development to distinguish methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) *Staphylococcus aureus* strains; two primary approaches will be described.

**2:50 Rapid Detection of Beta-Lactamase Activity in Clinical Specimens by Electrospray LC/MS/MS**
Michael E. Hodsdon, M.D., Ph.D., Associate Professor of Laboratory Medicine and Pharmacology, Yale University School of Medicine

Carbapenemase-expressing bacteria are associated with resistance to most modern antibiotics. Rapid detection is critical to live-saving clinical care and to prevent the spread of outbreaks. We present a rapid, liquid chromatography-coupled, electrospray ionization mass spectrometric assay that detects carbapenemase activity within hours from complex biologic matrices. We are validating this method on both bacterial isolates and primary clinical specimens.

**3:20 Sponsored Presentation (Opportunity Available)**

**3:35 Refreshment Break in the Exhibit Hall with Poster Viewing**

**4:10 Digging Deeper: Improving Results through Detailed Analysis of MALDI-TOF Data**
Mark Fisher, Ph.D., Assistant Professor of Pathology, The University of Utah, ARUP Institute for Clinical and Experimental Pathology

MALDI-TOF is rapidly becoming an accepted identification method. Current platforms accurately identify a broad range of organisms, but yield ambiguous results for some clinically relevant pathogens. Detailed analysis of the data at both the scoring and spectral levels can allow for better resolution and more reliable results.

**4:40 Next Generation Molecular Diagnostics: MALDI-TOF versus PCR/ESI-MS**
Robert Bonomo, M.D., Associate Professor of Medicine, Division of Infectious Disease and HIV Medicine, Case Western Reserve University

The field of molecular diagnostics is rapidly changing and new platforms are introduced regularly. At present clinicians must decide the advantages and disadvantages of choosing between technologies that identify pathogens alone from technologies that reveal the resistance determinants present in bacteria. Each approach assists with decisions to initiate therapy. A comparison of technologies that use mass spectrometry (MALDI-TOF and PCR/ESI-MS) will be examined.

**5:10 Wine and Cheese Pairing Welcome Reception in the Exhibit Hall with Poster Viewing**

**6:10 Close of Day**

**WEDNESDAY, AUGUST 22**

7:30 am Problem Solving Breakout Discussions with Continental Breakfast

**Applying Mass Spec-Based Methods to Infectious Disease (cont’d)**

**8:25 Chairperson’s Opening Remarks**
Richard R. Drake, Ph.D., Professor and Director, MUSC Proteomics Center, Medical University of South Carolina

**8:30 Matrix-Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry in the Clinical Microbiology Laboratory in 2012**
Robin Patel, M.D., Chair, Division of Clinical Microbiology, Consultant, Divisions of Clinical Microbiology and Infectious Diseases, Professor of Microbiology and Medicine, College of Medicine, Mayo Clinic

Matrix-assisted laser desorption ionization time of flight mass spectrometry allows identification of a wide range of types of bacterial and fungal colonies growing on plates within minutes, without the need for traditional time-consuming and expensive identification tools. This technology is rapidly gaining use in clinical microbiology laboratories worldwide. This presentation will overview the position of matrix-assisted laser desorption ionization time of flight mass spectrometry in clinical microbiology laboratories in 2012, addressing strengths and weaknesses.

**9:00 MALDI-TOF in the Mycobacteriology Laboratory and Direct Susceptibility Testing from Blood Cultures: Are They Now Reality?**
Nathan A. Ledeboer, Ph.D., Assistant Professor of Pathology, Medical College of Wisconsin

We evaluated the performance of a new Biotyper MALDI-TOF extraction method and library for identification of Mycobacterium spp compared to HPLC. Using a modified reference spectral library created with silica bead extraction resulted in a final identification rate of 94.6%. Further, detection of ampicillin and gentamicin resistance was measured in Enterobacteriaceae using MALDI and initial data indicates high sensitivity.

**9:30 Sponsored Presentation (Opportunity Available)**

**10:00 Coffee Break in the Exhibit Hall with Poster Viewing**

**10:30 Diagnosis of Periprosthetic Joint Infection**
Javad Parvizi, M.D., FRCS, Vice Chairman, Research; Director, Clinical Research, Rothman Institute

There are many challenges in diagnosis of PJI, most important of which relates to the lack of an absolute diagnostic test. A workgroup convened by the AAOS proposed an evidence based algorithmic approach. Our center and many others have identified molecular markers that can be utilized for more accurate diagnosis. I will discuss some of the molecular strategies that can be used.

**10:55 MALDI-TOF for Routine Identification of Bacteria and Fungi in the NIH Clinical Center Microbiology Laboratory**
Daniel P. Fedorko, Ph.D., Microbiologist, NIH/CC/DLM/Microbiology Service

The use of MALDI-TOF to identify anaerobic bacteria isolated from clinical specimens means the clinical microbiology laboratory no longer has to perform presumptive identifications using rapid tests or tests that require growth of suspect anaerobes. Identification of both aerobes and anaerobes growing from primary culture plates of an aerobic culture can be rapidly and accurately identified by MALDI-TOF.
Next Generation Dx Summit | 10

challenges and future considerations will be discussed. Unmet diagnostic needs, regulatory technologies including unit test systems designed for point-of-care diagnostics, arrays, appropriately manage patient care, and in certain cases reduce the risk of transmission within the community and health care settings. This lecture will provide an overview of laboratories, carries a significant economic burden and is compounded by the possibility of multiple aetiologies, both infectious and non-infectious. The results from a prospective study comparing xTAG GPP to standard protocols will be presented.

Mass Spectrometry in Clinical Microbiology

3:50 Advancing Diagnostics...Saving Lives: How Rapid Diagnostic Microbiology Can Make a Difference

Donna M. Wolk, M.H.A., Ph.D., D.(ABMM), Division Chief, Clinical and Molecular Microbiology; Associate Professor, Pathology and Medicine, Arizona Health Science Center and University Medical Center

Over the last decade, the Medical Diagnostic Laboratory Sciences community gained access to the proliferation of new and rapid diagnostic technology, largely based in the fields of genomics and proteomics. With access to emerging technology comes the responsibility for prudent stewardship of healthcare resources, supported by the application of evidence-based interventions that encompass the contemporary practice of Laboratory Medicine. This session will review the applications of mass spectrometry in clinical microbiology and describe its implementation in an academic medical center.

4:20 Improved Diagnosis of Gastroenteritis using the xTAG Gastrointestinal Pathogen Panel Multiplexed Molecular Assay

Richard Janeczko, Ph.D., Vice President, Emerging Markets & Technologies, Luminex Corporation

Gastroenteritis (GI) is one of the most common infections in both hospital and community patients. Management of these patients imposes strains on healthcare resources, carries a significant economic burden and is compounded by the possibility of multiple aetiologies, both infectious and non-infectious. The results from a prospective study comparing xTAG GPP to standard protocols will be presented.

4:35 Sponsored Presentation (Opportunities Available)

4:50 PCR-ESI-TOF-MS-Based Diagnostics Provide Unprecedented Sensitivity, Specificity, and Inclusivity in the Detection and Characterization of Infectious Diseases

Garth D. Ehrlich, Ph.D., Executive Director, Center for Genomic Sciences, Allegheny-Singer Research Institute

We have used the Ibis technology in multiple comparative studies with culture to evaluate the bacteriology of numerous infectious and inflammatory conditions including: total joint failures; osteoarthritis, bony non-union, ACL repair failure, chronic non-healing wounds, vaginal and uterine microbiomes and infections, urinary and male genital tract infections, and surgical site infections.

5:20 Digging Deeper: Improving Results through Detailed Analysis of MALDI-TOF Data

Mark Fisher, Ph.D., Assistant Professor of Pathology, The University of Utah, ARUP Institute for Clinical and Experimental Pathology

MALDI-TOF is rapidly becoming an accepted identification method in the clinical microbiology laboratory. Current platforms accurately identify a broad range of organisms, but yield ambiguous results for some clinically relevant pathogens. Detailed analysis of the data at both the scoring and spectral levels can allow for better resolution and more reliable results.

5:50 Close of Mass Spectrometry Conference
TUESDAY, AUGUST 21

7:30 am Registration and Morning Coffee

Case Studies of Recent Combined Drug and Diagnostic Approvals

8:30 Chairperson's Opening Remarks
Erling Thor Donnelly, Ph.D., R.A.C., Director, Worldwide Regulatory Strategy, Pfizer, Inc.

8:40 XALKORI & ALK FISH Test Approval: Pharmaceutical Perspective
Erling Thor Donnelly, Ph.D., R.A.C., Director, Worldwide Regulatory Strategy, Pfizer, Inc.

The simultaneous submission and approval of Pfizer’s XALKORI (crizotinib) and Abbott Molecular’s ALK break-apart FISH companion diagnostic in 2011 presented unique clinical development and regulatory challenges, requiring novel approaches as well as close collaboration between Pfizer, Abbott, CDER, and CDRH. XALKORI was approved only five years after entering clinical trials on the strength of its clinical data in ALK-positive NSCLC patients and unique regulatory strategy.

9:10 XALKORI & ALK FISH Test Approval: Diagnostics Perspective
Pamela L. Swatkowski, Director, Regulatory Affairs, Abbott Molecular, Inc.

The simultaneous submission and approval of Pfizer’s XALKORI (crizotinib) and Abbott Molecular’s ALK break-apart FISH companion diagnostic in 2011 presented unique clinical development and regulatory challenges, requiring novel approaches as well as close collaboration between Pfizer, Abbott, CDER, and CDRH. The Abbott Molecular ALK Break Apart FISH test development timeline was accelerated from three years to two years and FDA approval was achieved in just five months.

9:40 Paving the Way for Contemporaneous Diagnostic Co-Development and Health Authority Review: The Zelboraf Story
Linda Burdette, Ph.D., Director, Drug Regulatory Affairs, F. Hoffmann-La Roche, Inc.

Co-development of the BRAF-targeted therapy, ZELBORAF™ (vemurafenib) with its companion diagnostic, the cobas® 4800 BRAF V600 Mutation Test highlights aspects of the regulatory pathway described in FDA’s 2011 draft guidance, In Vitro Companion Diagnostic Devices, and the resulting accelerated process for contemporaneous approval of a drug and companion diagnostic test. The ZELBORAF story also demonstrates the need for an integrated global regulatory strategy for marketing approval in a targeted population.

10:10 Coffee Break

11:00 Paving the Way for Contemporaneous Diagnostic Co-Development and Health Authority Review: The Cobas 4800 Braf Mutation Test Story
Lesley Farrington, Senior Manager, Regulatory Affairs, Roche Molecular System

An overview of the regulatory interactions and lessons learned on the road to contemporaneous review and approval of the companion diagnostic, cobas® 4800 BRAF V600 Mutation Test, with the selective BRAF inhibitor, ZELBORAF™ (vemurafenib) for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation. The accelerated Dx/Rx approval also demonstrates the ability to accelerate diagnostic development and registration timelines in coordination with drug development programs, while maintaining compliance and quality.

11:30 PANEL DISCUSSION: What’s Past is Prologue: A Regulatory Perspective on Contemporaneous Diagnostic Co-Development
Moderator: Janet Jenkins-Shoveller, Senior Director, Regulatory Group, Intelligence and Policy, US Pharmaceutical Development Regulatory, Genentech – A Member of the Roche Group

A Panel of Experts will discuss:
• Lessons learned from contemporaneous diagnostic co-development successes

• The current and future regulatory environment
• How the most recent “poster-child” success stories, along with the regulatory environment and interested stakeholders, will shape the future of personalized medicine.

Panelists:
Erling Thor Donnelly, Ph.D., R.A.C., Director, Worldwide Regulatory Strategy, Pfizer, Inc.
Pamela L. Swatkowski, Director, Regulatory Affairs, Abbott Molecular, Inc.
Linda Burdette, Ph.D., Director, Drug Regulatory Affairs, F. Hoffmann- La Roche, Inc.
Lesley Farrington, Senior Manager, Regulatory Affairs, Roche Molecular System

Jeff Allen, Ph.D., Executive Director, Friends of Cancer Research

12:30 Enjoy Lunch on Your Own

Working With Regulators

1:45 Chairperson’s Remarks
Maham Ansari, M.S., Senior Associate, Regulatory Affairs, US Strategic Regulatory Services, OptumInsight

1:50 FDA Draft Guidances: Overview, Key Messages and Impact
Debra Rasmussen, RAC, MBA, Senior Director, Regulatory Affairs, Johnson & Johnson

2:20 Demystifying Bridging Studies
Marina V. Kondratovich, Ph.D., Associate Director for Clinical Studies, Personalized Medicine, OIVD, CDRH, U.S. Food and Drug Administration

In a “bridging study”, clinical samples tested initially with a clinical trial assay (CTA) are re-tested with a market ready assay (MRA) to support approval/clearance of the MRA. We discuss why high levels are required for positive and negative agreement of MRA with CTA and various challenges with such studies (e.g., unavailable samples, missing re-test results, impact of discordance between the two assays on drug efficacy).

2:50 Q&A with Speakers

LABORATORIES’ PERSPECTIVE

3:20 FDA Approved Laboratory IVD Assays as Companion Diagnostics: A New Paradigm?
C. Donald Kafader II, Director, Regulatory Affairs, Esoterix Clinical Trials Services, a Division of LabCorp

IVD manufacturers have little incentive to seek and obtain FDA approval for some assays unless there is a substantial potential market for them to sell into. An alternative exists where centralized testing can support the need for a companion diagnostic assay. Laboratories are seeking FDA approvals for assays run only within their facilities. This new paradigm brings new concerns to the diagnostic laboratory and to the FDA.

3:35 Refreshment Break in the Exhibit Hall with Poster Viewing

4:10 Laboratory Developed Tests and Their Place in the Genomic Medicine Era: A CLIA Laboratory Perspective on Companion Diagnostics
Elaine Lyon, Ph.D., Medical Director, Genetics Division; Co-Medical Director, Pharmacogenomics; Co-Director, Clinical Molecular Genetics Fellowship Program, ARUP Laboratories

Clinical laboratories may develop and validate their own methods following CLIA regulatory requirements as laboratory-developed tests (LDT). They may also validate FDA-cleared products for an off-label use (such as additional sample types) as LDTs. This presentation will discuss factors CLIA-certified laboratories consider in deciding to use an FDA-cleared IVD, an off-label use or an in-lab developed assay. The role of LDTs and clinical validations is put into an historical, as well as a near-future genomic medicine, perspective
4:40 CLIA, CAP, GCLP and the FDA: Clinically Certified Lab Processes Enable New Approaches to Therapeutic Compound and Companion Diagnostic Development.

Tera Eerkes, Ph.D., CSO, iGenix, Inc.

High-throughput genotyping, massively parallel sequencing (NGS) and other high-complexity techniques have made it possible to design clinical trials to maximize compound efficacy, minimize toxicity, and pre-segregate patient populations. However, there is a dearth of specific guidance on how these new data and techniques should be incorporated and utilized for FDA submissions. This talk will explore joining these revolutionary techniques and data with existing “best-in-class” regulatory certification processes, as well as future regulatory guides, to maximize successful FDA application potential.

5:10 Wine and Cheese Pairing Welcome Reception in the Exhibit Hall with Poster Viewing

6:10 Close of Day

WEDNESDAY, AUGUST 22

7:30 am Problem Solving Breakout Discussions with Continental Breakfast

New Paradigms in Regulatory Approaches

8:25 Chairperson’s Opening Remarks
Debra Rasmussen, RAC, MBA, Senior Director, Regulatory Affairs, Johnson & Johnson

8:30 Whole Genome Sequencing as Companion Diagnostic: Regulatory Considerations
Melina Cimler, Vice President, Quality & Regulatory Affairs, Illumina, Inc.

9:00 Looking into the Global Regulatory Future of Companion Diagnostics and Personalized Medicine
Maham Ansari, M.S., Senior Associate, Regulatory Affairs, US Strategic Regulatory Services, OptumInsight

The global regulatory landscape for companion diagnostics (CDx) is changing very fast making it extremely challenging for industry to keep up with the increasing demands of the regulators. This presentation will examine the changing regulatory framework for CDx in complex and key jurisdictions like Japan, China, Canada, US, and EU and provide tips on what is required to obtain successful market approval for these niche products in these countries. An overview of global design & development requirements will also be provided.

9:30 EU Regulatory Environment Around Companion Diagnostics
Bruno Flamion, M.D., Ph.D., Professor of Physiology and Pharmacology, University of Namur, Belgium, and Chairman, Scientific Advice Working Party, The European Medicines Agency (EMEA)

10:00 Coffee Break in the Exhibit Hall with Poster Viewing

10:30 Companion Diagnostics and Personalized Medicine: The FDA Perspective
Alberto Gutierrez, Ph.D., Office of in vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration

11:15 Transition to Plenary Session

11:50 Plenary Keynote Discussion

Regulation of LDTs and RUOs
Alberto Gutierrez, Ph.D., Deputy Director, Office of in vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration

Moderated by: Franklin R. Cockerill, III, M.D., Ann and Leo Markin Professor of Microbiology & Medicine; Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine; President and CEO, Mayo Medical Laboratories and Mayo Collaborative Services, Inc.

12:45 pm Enjoy Lunch on Your Own

Plenary Keynote

1:45 Views of the Laboratory Industry on Regulatory Issues
Alan Mertz, President, American Clinical Laboratory Association (ACLA)

2:10 Views of Diagnostics Manufacturers on Regulatory Issues
Andrew C. Fish, Executive Director, AdvaMedDx

2:30 Close of Regulatory Compliance in Drug-Diagnostic Co-Development Conference

Hotel & Travel Information

Conference Hotel: The Hyatt Regency on Capitol Hill, Washington, DC
400 New Jersey Avenue Washington, DC 20001
Tel: 202-737-1234
Room Rate: $195 s/d
Reservation Cutoff: July 20, 2012
Please visit our conference website to make your reservation online or call the Hotel directly to reserve your sleeping room accommodations. You will need to identify yourself as a Cambridge Healthtech Institute conference attendee to receive the discounted room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space- and rate-availability basis. Rooms are limited, so please book early.

Flight Discounts:
American Airlines
Special discounts have been established with American Airlines for this conference:
• Call 1-800-433-1790 and use Conference Code 9482BG
• Go online at www.aa/group.com enter Conference code 9482BG in promotion discount box
• Contact our designated travel agent, Wendy Levine at 1-877-559-5549 or wendy.levine@protravelinc.com

Car Rental Discounts:
Special discount rentals have been established with Hertz for this conference.
• Call HERTZ, 800-654-3131 use our Hertz Convention Number (CV): 04KL0003
• Go online www.hertz.com use our Hertz Convention Number (CV): 04KL0003

NextGenerationDx.com
Recommended Pre-Conference Short Course*  
Introducing Mass Spectrometry into a Clinical Laboratory  
*Separate registration required, please see page 3 for details

WEDNESDAY, AUGUST 22

11:00 am Registration

11:50 PLENARY KEYNOTE DISCUSSION

Regulation of LDTs and RUOs  
Alberto Gutierrez, Ph.D., Deputy Director, Office of in vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration

Moderated by: Franklin R. Cockerill, III, M.D., Ann and Leo Markin Professor of Microbiology & Medicine; Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine; President and CEO, Mayo Medical Laboratories and Mayo Collaborative Services, Inc.

12:45 pm Enjoy Lunch On Your Own

PLENARY KEYNOTE

1:45 Views of the Laboratory Industry on Regulatory Issues  
Alan Mertz, President, American Clinical Laboratory Association (ACLA)

2:10 Views of Diagnostics Manufacturers on Regulatory Issues  
Andrew C. Fish, Executive Director, AdvMedDx

2:30 Refreshment Break in the Exhibit Hall with Poster Viewing

3:15 Chairperson’s Opening Remarks  
Nathan A. Ledebour, Medical College of Wisconsin

3:20 SPOTLIGHT PRESENTATION: Innovative Technologies from Mass Spec to Multiplex Technologies  
Christine C. Ginocchio, Ph.D., M.T. (ASCP), Chief, Division of Infectious Disease Diagnostics, Department of Pathology and Laboratory Medicine; Professor, Hofstra University North Shore-LIJ School of Medicine North Shore-LIJ Health System Laboratories

This lecture will provide an overview of technologies including unit test systems designed for point-of-care diagnostics, arrays, droplet digital PCR, and mass spectroscopy analysis. Unmet diagnostic needs, regulatory challenges and future considerations will be discussed.

Mass Spectrometry in Clinical Microbiology

3:50 Advancing Diagnostics...Saving Lives: How Rapid Diagnostic Microbiology Can Make a Difference  
Donna M. WoIk, M.H.A., Ph.D., D.(ABMM), Division Chief, Clinical and Molecular Microbiology; Associate Professor, Pathology and Medicine, Arizona Health Science Center and University Medical Center

Over the last decade, the Medical Diagnostic Laboratory Sciences community gained access to the proliferation of new and rapid diagnostic technology, largely based in the fields of genomics and proteomics. This session will review the applications of mass spectrometry in clinical microbiology and describe its implementation in an academic medical center.

4:20 Improved Diagnosis of Gastroenteritis using the xTAG Gastrointestinal Pathogen Panel Multiplexed Molecular Assay  
Richard Janeczko, Ph.D., Vice President, Emerging Markets & Technologies, Luminex Corporation

Gastroenteritis (GI) is one of the most common infections in both hospital and community patients. Management of these patients imposes strains on healthcare resources, carries a significant economic burden and is compounded by the possibility of multiple aetiologies, both infectious and non-infectious. The results from a prospective study comparing xTAG GPP to standard protocols will be presented.

4:35 Sponsored Presentation (Opportunity Available)

4:50 PCR-ESI-TOF-MS-Based Diagnostics Provide Unprecedented Sensitivity, Specificity, and Inclusivity in the Detection and Characterization of Infectious Diseases  
Garth D. Ehrlich, Ph.D., Executive Director, Center for Genomic Sciences, Allegheny-Singer Research Institute

We have used the ibis technology in multiple comparative studies with culture to evaluate the bacteriology of numerous infectious and inflammatory conditions including: total joint failures; osteoarthritis, bony non-union, ACLrepair failure, chronic non-healing wounds, vaginal and uterine microbiomes and infections, urinary and male genital tract infections, and surgical site infections.

5:20 Imaging the Effect of the Microbiome on Gut Metabolism with Mass Spectrometry with Real-Time Analysis of Bacterial Metabolic Output  
Christopher Rath, Ph.D., Scientist, Dorrestein Laboratory, University of California, San Diego

Changes in gut microbiome populations have been correlated with disease status. We applied imaging mass spectrometry to localize metabolites in gnotobiotic mouse models of the human gut microbiome. Inflammation-associated molecules with altered spatial distributions include: amino-acids, bile-acids, polysaccharides, and lipids. Identifications were validated by semi-quantitative LCMS/GCMS. Findings were then correlated to human fecal samples, pure bacterial cultures, and transcriptomics analysis.

5:50 Close of Day

6:30 - 8:30 pm Dinner Short Courses*  
*Separate registration required, please see page 3 for details

THURSDAY, AUGUST 23

7:30 am Problem Solving Breakout Discussions with Continental Breakfast

Multiplex Diagnosis of Infectious Disease

8:25 Chairperson’s Opening Remarks  
Charles Chiu, University of California San Francisco School of Medicine

8:30 Multiplex Nucleic Acid Tests for Respiratory Pathogens: Technology, Applications and Clinical Relevance  
Frederick S. Nolte, Ph.D., D(ABMM), F(AAM), Professor, Pathology and Laboratory Medicine; Vice Chair, Laboratory Medicine; Director, Clinical Laboratories, Medical University of South Carolina

Respiratory viruses are responsible for significant morbidity and mortality especially in children, the elderly and immunocompromised individuals. The emerging technologies for multiplex nucleic acid-based tests for the detection of respiratory viruses will be reviewed. The use of these technologies in clinical laboratories to provide comprehensive diagnostic tests for these pathogens and their clinical impact will be discussed.

9:00 Using Next-Generation Sequencing and Microarrays for Multiplexed Testing in the Clinical Microbiology Lab  
Charles Chiu, M.D., Ph.D., Assistant Professor, Departments of Laboratory Medicine and Medicine, Infectious Diseases, University of California San Francisco School of Medicine

Pan-pathogen microarrays such as the UCSF ViroChip and unbiased deep sequencing have proven effective for broad-based identification of pathogens in clinical specimens. Significant challenges remain, however, in adapting these technologies for routine use in clinical and public health settings.
9:30 Molecular Diagnostic Platforms for Detecting Drug Resistance in Fungal Pathogens
David S. Perlin, Ph.D., Executive Director and Professor, Public Health Research Institute & UMDNJ Regional Biocounterme Laboratory, International Center for Public Health, UMDNJ-New Jersey Medical School
Early detection of fungi in clinical specimens with rapid evaluation of drug susceptibility has the potential to improve survival of patients with invasive mycoses. A variety of robust real-time RNA- or DNA-amplification and detection platforms are available that provide simultaneous species identification and high fidelity allelic discrimination of resistance markers.

10:00 Companion Diagnostic using Multiparameter Flow Cytometry for Nucleoside Transporter hENT1 in Acute Myeloid Leukemia
Bruce H. Davis, M.D., President & Founder, Trillium Diagnostics, LLC
The human Equilibrative Nucleoside Transporter 1 (hENT1) transports nucleoside analogs such as cytarabine (ara-C) and gemcitabine into the cells. We developed a flow cytometric assay for hENT1 to identify patients that might benefit from ara-C alternatives, such as ElacytarabineTM due to low hENT1 expression to serve as a companion diagnostic. We report our experience with the flow cytometric assay for hENT1 in blood (PB) and bone marrow (BM) specimens using a ratiosometric method. The studies demonstrate variable hENT1 expression in leukocytes and nearly a ten-fold range of hENT1 expression among AML blasts. This diagnostic assay for hENT1 expression could be integrated into clinical practice and help personalize medicine by rapidly identifying alternative AML therapies when hENT1 expression is decreased.

10:15 Coffee Break in the Exhibit Hall with Poster Viewing

From Multiplex to Deep Sequencing in ID

10:45 FEATURED PRESENTATION: Applying NGS Sequencing to Diagnostic Virology
Gregory A. Storch, M.D., Ruth L. Sitelman Professor of Pediatrics, Professor of Medicine and of Molecular Microbiology; Director, Pediatric Infectious Diseases and Pediatric Laboratory Medicine; Medical Director, Clinical Laboratories; St. Louis Children’s Hospital
High throughput sequencing offers the appeal of an open approach to viral detection that can reveal the presence of a broader range of pathogens than viral isolation, antigen detection or amplification-based technologies. The challenges of using high throughput sequencing in a diagnostic virology lab, and data from an on-going study comparing sequencing to an extensive panel of PCR assays will be presented.

11:15 Principles and Recommendations for the Implementation of NGS into Diagnostic Labs
Amy Gargis, ORISE Fellow, Centers for Disease Control and Prevention
Current professional and regulatory standards that address the quality of NGS are minimal at this time. This presentation will describe the outcomes from a national workgroup that developed principles and guidance for NGS that considered test validation, quality control procedures, proficiency testing, and reference materials.

11:45 Sequencing Methods in Diagnostic Laboratory Medicine
Andrea Ferreira-Gonzalez, Ph.D., Professor of Pathology & Director, Molecular Diagnostics Laboratory, VCUHS

12:15 pm PANEL DISCUSSION: MultiplexTesting Platforms & Technologies for the Clinical Laboratory
Moderator: Charles Chiu, University of California San Francisco School of Medicine
Sponsored spotlight presentations from technology & platform providers supporting multiplex testing. (Opportunities Available)

12:45 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

1:45 Session Break

Hcv and Hpv – Clinical Diagnostics

2:00 Chairperson’s Remarks
Christine C. Ginocchio, Hofstra University North Shore-LIJ School of Medicine North Shore-LIJ Health System Laboratories

2:05 FEATURED PRESENTATION: Monitoring HCV RNA in the Era of Potent Anti-Viral Therapy
Mitchell L. Shiffman, M.D., Liver Institute of Virginia, Bon Secours Virginia Health System
Chronic HCV is the most common cause of chronic liver disease, cirrhosis and liver cancer in the USA. In 2011 the first 2 direct acting anti-viral agents for HCV were approved by the US FDA. Over 20 protease and/or polymerase inhibitors are now under development. The treatment of chronic HCV requires highly sensitive assays to measure HCV RNA and knowledge of how to utilize the results of these assays to assess response and guide HCV treatment.

2:35 What’s New in Viral Hepatitis and HIV Testing?
Joseph D. Yao, M.D., Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic & Mayo Medical Laboratories
This talk will cover: Hepatitis A - serologic and molecular test updates; Hepatitis B - quantitative HBsAg serologic and HBV molecular testing; Hepatitis C - impact of DAA on HCV RNA quantification and HCV resistance testing; and Hepatitis E - serologic and molecular testing.

3:05 Hepatitis C Virus Genotyping to Detect Drug Resistance to Direct Acting Antiviral Agents: From the Bench to the Clinic
Michael J. Kozal, M.D., Professor of Medicine, Division of Infectious Diseases, Yale School of Medicine; Director, Yale HIV Clinical Trials Program; Chief, Section of Infectious Diseases, VA CT Healthcare System
Combinations of direct acting antivirals (DAAs) have cured some HCV-infected patients without the use of pegylated interferon and ribavirin. However, amino acid changes in the NS3, NS5A and NS5B genes can lead to high-level drug resistance and are strongly associated with treatment failure with DAAs. This talk will review current methods and new emerging technologies used to detect DAA drug resistance and how these new assays may be employed in the clinic.

3:35 Novel Sample Storage and Transport by ViveST for Downstream HCV Viral Load and Genotypic Testing
Daniel R. McClennon, CSO, bioMONTR Laboratory, a division of McClennon LLC. Infectious disease monitoring often requires collection sites to ship patient samples to reference testing laboratories. These samples require careful temperature control and special packaging. We will describe performance of ViveST, a novel dried ambient transportation matrix, to frozen plasma for use with commercially available HCV viral load and genotypic assays.

4:05 SPOTLIGHT PRESENTATION: Cytomegalovirus in Transplant Testing: Challenges and the Promise of Standardization
Randall T. Hayden, M.D., , Director, Clinical and Molecular Microbiology, Member, Department of Pathology, St. Jude Children’s Research Hospital
Cytomegalovirus (CMV) viral load testing, most commonly by real-time PCR has become a mainstay of post-transplant care. However, the interpretation of such testing is fraught with challenges, largely due to suboptimal assay precision and the lack of standardized quantitative controls. An overview of the role of CMV testing will be presented, along with issues related to result variability and standardization.

4:35 Close of Infectious Disease Conference
The Rheonix CARD® system is able to automatically process a wide range of clinical specimens for companion diagnostic applications. Such samples as buccal swabs, whole blood, fresh tissue and FFPE samples can be placed into the system which will automatically lyse cells, extract and purify DNA, multiplex PCR amplify targets of interest and then detect the resulting amplicons on an integrated DNA microarray. Examples of using the CARD technology to detect the presence of SNPs associated with warfarin sensitivity, Plavix sensitivity and KRAS markers will be provided.

4:35 Single Molecule Arrays (SiMoA) for Ultrasensitive Protein Detection in Companion Diagnostics
David C. Duffy, Ph.D., Vice President, Research, Quanterix Corporation
SiMoA is a game-changing technology for the quantification of low concentrations of proteins in blood. This fully automated platform enables high throughput, multiplexed measurement of proteins at low cost. We will describe the potential for SiMoA to have a dramatic impact on the development of companion diagnostics for antibody therapeutics.

4:50 A New Paradigm for Advancing Personalized Medicine: The Contract Diagnostics Organization
Philip D. Cotter, Ph.D., F.A.C.M.G., Co-Founder, ResearchDx, LLC

5:05 Using Protein Microarray Technology to Screen Ultra-Specific mAbs for Diagnostic Purpose
Donghui Ma, Ph.D., Director, Immunology, OriGene Technologies, Inc.
Antibody with cross-reactivity can create unexpected side effects or false diagnostic reports if used for clinical purposes. By using high density protein microarray chip technology, we discovered that a number of well known diagnostic mAbs are not specific and we were able to generate the corresponding UltraMABs with extreme target specificity and ultra-performance.

5:20 Finding the Right Tool: Tailoring the Assay to the Clinical Need
Jamie Platt, Ph.D., Scientific Director, Advanced Sequencing, Quest Diagnostics Nichols Institute
There are several categories of genetic variants associated with disease, drug response, or cancer prognosis. These include point mutations, triplet repeat expansions, small insertions and deletions (in-dels), large deletions and duplications, chromosomal translocations, and copy number abnormalities. There is an extensive variety of platforms to detect the variations. The concept that any single test, even whole genome sequencing (WGS) will be able to detect all of these variants is naive. This talk will use examples of clinical and companion diagnostic scenarios which would mandate use of a particular technology to optimize sensitivity and specificity and minimize costs.

5:50 Predicting Tumor Response to Targeted Therapy using Multiplexed Tissue Protein Analysis
John Gillespie, M.D., Director, Medical Affairs, 2020 GeneSystems, Inc.
Layered immunohistochemistry (LiHC) permits the multiplex analysis of biomarkers in FFPE tissue sections. Analysis of biomarkers along the mTOR pathway using LiHC was performed on breast and kidney cancer samples from patients treated with trastuzumab and temsirolimus, respectively. In both cases a small set of biomarkers correctly identified responders and non-responders with 90% or better accuracy. This is a substantial improvement over other tests currently used to predict response.

6:05 Close of Day
6:30-8:30 pm Dinner Short Courses*
*Separate registration required, please see page 3 for details

Recommended Pre-Conference Short Courses*
- Latest Advances in Molecular Pathology
- Deal Making in Companion Diagnostics
- Next Generation Sequencing in Molecular Pathology

*Separate registration required, please see page 3 for details
THURSDAY, AUGUST 23

7:30 am Problem Solving Breakout Discussions with Continental Breakfast

Pharma-IVD Partnerships: Striving for Fair and Effective Models

8:10 Chairperson’s Opening Remarks

8:15 Co-Development of Zelboraf and the Cobas BRAF V600 Test, and Beyond
Walter Koch, Ph.D., Vice President & Head, Global Research, Roche Molecular Systems

8:45 How to Partner with Pharma and Enable Value Capture for Both Parties
Peter Collins, Ph.D., Vice President & Head, Diagnostics, GlaxoSmithKline Biologicals

9:15 Diagnostic Partnerships in Biomarker Identification, Development, and Commercialization
Matthew J. Hawrylyk, Ph.D., Director, Business Development, Foundation Medicine, Inc.

9:45 Funding for Companion Diagnostics in the US Market: Stakeholders and Trends
Gavin Erickson, Principal Consultant, GfK Bridgehead

10:15 Coffee Break in the Exhibit Hall with Poster Viewing

10:45 Towards Effective Drug-Diagnostic Co-Development and Commercialization – How Do We Get There?
Rainer Metzger, Ph.D., Vice President, Pharma Partnerships, Leica Biosystems

11:15 Evolving Effective Partnering Models for Rx/Dx Co-Development and Commercialization
Andrea Lauber, Ph.D., Global Head, Transactions for Clinical Biomarkers and Pharmacodiagnostics, Bristol-Myers Squibb

11:45 Challenges Posed to Dx Business Models by Companion Diagnostics and Personalized Medicine
Joseph V. Ferrara, President, Boston Healthcare

12:15 pm PANEL DISCUSSION: Increasing Partnership Value for Diagnostics Partners

1:00 Luncheon Presentation I
A Blood-Based Protein Biomarker Approach to Companion Diagnostic Development
Dominic Eisinger, Ph.D., Director, Strategic Development, Myriad RBM
  • Choosing the right patients – disease segmentation in heterogeneous diseases
  • Case study of a successful program: CDx diagnostic partnership with Pharma
  • Myriad RBM partnership models: flexibility, shared risk, and strategic fit.

1:30 Luncheon Presentation II
Hire Right the First Time; Interview Techniques That Work
Tara Kochis, President, Slone Partners

Evidence Generation for Reimbursement Decisions

2:00 Chairperson’s Remarks

2:05 Roadmap for Demonstrating Clinical Utility of Molecular Diagnostics: Experience with the 92-Gene Assay for Cancer Classification, CancersType ID
Catherine A. Schnabel, Ph.D., Senior Director, Medical & Scientific Affairs, bioTheranostics, Inc.

2:35 A Payer’s Perspective: Reimbursement of Companion Diagnostics
David A. Dworaczyk, Ph.D., COO, Meta Diagnostic

3:05 PANEL DISCUSSION
Moderator: Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors
Additional Panelists:
  • Elaine K. Jeter, M.D., Medical Director, Palmetto GBA
  • Sheila D. Walcoff, Esq., Founding Principal, Goldbug Strategies LLC and Counsel for the Coalition for 21st Century Medicine

4:00 Close of Companion Diagnostics Conference
WEDNESDAY, AUGUST 22

11:00 am Registration

11:50 PLENARY KEYNOTE DISCUSSION

Regulation of LDTs and RUOs
Alberto Gutierrez, Ph.D., Deputy Director, Office of in vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration

Moderated by: Franklin R. Cockerill, III, M.D., Ann and Leo Markin Professor of Microbiology & Medicine; Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine; President and CEO, Mayo Medical Laboratories and Mayo Collaborative Services, Inc.

12:45 pm Enjoy Lunch On Your Own

PLENARY KEYNOTE

1:45 Views of the Laboratory Industry on Regulatory Issues
Alan Mertz, President, American Clinical Laboratory Association (ACLA)

2:10 Views of Diagnostics Manufacturers on Regulatory Issues
Andrew C. Fish, Executive Director, AdvaMedDx

2:30 Refreshment Break in the Exhibit Hall with Poster Viewing

Future of Pricing and Reimbursement in Diagnostics

3:00 Chairperson’s Opening Remarks
Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors

3:05 Simulation Reduces Risk Earlier in IVD Instrument Development Programs
Walter Glade, Manager, Business Development, KMC Systems, Inc.

IVD instrument development programs carry degrees of risks depending on marketing requirements, business value proposition and/or technology maturity. Early simulation has proven effective in exposing concealed requirements, design conflicts, and technical risks. Simulation models allow the resolution of these issues, and the ability to revise concepts and make informed tradeoffs before substantial development expenditures and capital commitments are made. This proven process provides a more robust business case analysis, optimizing parameters leading to cost effective instrument platforms and tests.

3:20 Launching Diagnostics into a Global Marketplace
Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors

This presentation will provide an overview of the necessary clinical, delivery model, business, and financial considerations for informed decision-making in entering new geographic markets.

Rina Wolf, Vice President, Commercialization Strategies, Consulting & Industry Affairs, Xfin

In this era of change, learn about recent updates on coding, coverage, reimbursement and pricing and discover how you can prepare yourself to respond. Through discussions of case studies, gain insights into what data and strategies are most effective to fully bring a test to market. This is the perfect session for our changing environment to find out what you will need to be successful in commercialization and techniques to translate your good science into good business.

4:05 Multiplex Molecular Assays from Discovery to the Clinic on FFPE Samples: Extraction-Free
Chris Roberts, Vice President, Medical Innovation, HTG Molecular

HTG’s qNPA enables analysis of FFPE tissue samples in a simple workflow process. The ability to measure dozens to hundreds of genes in a single micro well, along with the flexibility to use old or degraded samples, permits the use of retrospective cohorts in discovery and validation, and is important in clinical practice. HTG has an extensive publication record and clinical labs use qNPA today.

4:20 Partnering with Payers to Shift to Value-Based Reimbursement
Douglas Moeller, M.D., Medical Director, McKesson Health Solutions

Several critical trends in the market are making it more difficult for Laboratories to get reimbursed for the advanced diagnostic tests they perform. For many labs, partnering with Health Plans may be the answer to not only improve reimbursement, but move towards an environment where they are reimbursed on value. Attendees will gain an understanding of those trends impacting the reimbursement of molecular and genetic tests and uncover the opportunities to partner with payers to move towards value-based reimbursement.

Challenges of Stratified Medicine Commercialization

4:50 Industrialization of Next-Generation Diagnostics
Ali Tinazli, Ph.D., Director, Business Development & Sales, Sony DADC

Smart Consumables with microfluidic or optical features are prerequisites for emerging applications in the biomedical markets. The increasing complexity of such new products requires new manufacturing technologies. Sony DADC is applying its excellence in customized mass manufacturing to these highly sophisticated consumables in its new OEM business.

5:05 Multiplex Molecular Assays from Discovery to the Clinic on FFPE Samples: Extraction-Free
Chris Roberts, Vice President, Medical Innovation, HTG Molecular

HTG’s qNPA enables analysis of FFPE tissue samples in a simple workflow process. The ability to measure dozens to hundreds of genes in a single micro well, along with the flexibility to use old or degraded samples, permits the use of retrospective cohorts in discovery and validation, and is important in clinical practice. HTG has an extensive publication record and clinical labs use qNPA today.

5:20 What Defines Value Capture in Drug Diagnostic Co-Development
Peter Collins, Vice President, Personalized Medicine Diagnostics, GlaxoSmithKline

This talk will describe the fundamental components of Value Capture in an Rx/Dx setting. What is the value proposition to various stakeholders? What are the challenges involved in establishing value for drug, diagnostic and the combination? An assessment of the differences between commercializing a drug versus a typical diagnostic will be considered.

5:50 Addressing the Challenges of CDx Development and Commercialization: Perspectives from a Global IVD Leader
John F. Beeler, Ph.D., Director, Theranostics and Business Development, bioMerieux

The speaker will discuss bioMerieux’s successful theranostic partnering strategy with pharmaceutical developers. bioMerieux has developed a real-world knowledge of win-win deal terms, co-development strategies and alliance management. The speaker will discuss therapeutic development issues from the diagnostic developer perspective and will comment on the likely future evolution of commercializing companion diagnostics in this field.

6:30- 8:30 pm Dinner Short Courses*

The Future of Point-of-Care Diagnostics

*Separate registration required, please see page 3 for details
Navigating the Challenges of Personalized Medicine in Europe

8:25 Chairperson's Opening Remarks
Alain Huriez, M.D., Chairman, Epemed: European Personalized Medicine Association

8:30 Navigating Market Access in Europe
Alain Huriez, M.D., Chairman, Epemed

9:00 PANEL DISCUSSION:
Bruno Flamion, M.D., Ph.D., Professor of Physiology and Pharmacology, University of Namur, Belgium, and Chairman, Scientific Advice Working Party, The European Medicines Agency (EMEA)
Irene Norstedt, Deputy Head, DG Research and Innovation, Health Research: Personalised Medicine, European Commission
Nick Crabb, Associate Director, Diagnostics Assessment Programme, Centre for Health Technology Evaluation, National Institute for Clinical Excellence (NICE)
Fabien Calvo, M.D., Ph.D., Deputy General Director, National Cancer Institute, France

10:00 Novel Clinical Trial Design in IVD Development
Hua Gong, M.D., Ph.D., Executive Director, IVD, D-Target, a Premier Research Company

10:15 Coffee Break in the Exhibit Hall with Poster Viewing

10:40 Chairperson’s Remarks
Thomas F. Sonano, President & CEO, DOCRO, Inc.

10:45 Finding Real Customers in a Billion Dollar Market
Manfred Scholz, Ph.D., President, Scholz Consulting Partners LLC

11:00 What are some of the obstacles?

11:05 Question and Answer (Q&A) with Speakers

11:35 Q&A with Speakers

Commercialization Challenges for Next-Generation Sequencing

11:45 EXPERT PANEL
What are the actual commercial opportunities?
What is the best path forward?
IT: data management challenges

12:45 Luncheon Presentations
Innovative Partnering Strategies for Multiplex Companion Diagnostics
David Jackson, Ph.D., Vice President, Business Development, PrimeraDx

Intellectual Property & Innovation Following Prometheus & Myriad
Gregory Carlin, Principal, McKeon, Meunier, Carlin & Curfman, LLC

1:45 Session Break

Evidence Generation for Reimbursement Decisions

2:00 Chairperson’s Remarks

2:05 Roadmap for Demonstrating Clinical Utility of Molecular Diagnostics: Experience with the 92-Gene Assay for Cancer Classification, MTC-type ID
Catherine A. Schnabel, Ph.D., Senior Director, Medical & Scientific Affairs, bioTheranostics, Inc.

2:35 A Payer’s Perspective: Reimbursement of Companion Diagnostics
David A. Dvoraczky, Ph.D., COO, Meta Diagnostic

3:05 PANEL DISCUSSION
Moderator: Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors
Additional Panelists:
Elaine K. Jeter, M.D., Medical Director, Palmetto GBA
Sheila D. Walcoff, Esq., Founding Principal, Goldbug Strategies LLC and Counsel for the Coalition for 21st Century Medicine

4:00 Close of Commercialization of Molecular Diagnostics Conference

Moderator:
Andrew Fish, J.D., Executive Director, AdvaMed Dx

Panelists:
Meeting Informatics Challenges in a Genomic World
M. Michael Barnarda, Ph.D., Associate Professor of Human Genetics, Director, Center for Computational Genetics, GSPH; Associate Director, Center for Simulation and Modeling, University of Pittsburgh

In particular, evidentiary requirements of analytical validity, clinical validity, clinical utility and health effectiveness will be presented along with highlighting how the clinical value story is organized for various healthcare stakeholders.

In the era towards individualizing patient care, the changing landscape of molecular diagnostics presents many challenges to enabling clinical adoption and applicability of high complexity tests. This presentation will discuss the importance of accurate tumor classification in current paradigms of evidence-based patient management, overview perspectives and propose a framework for developing clinical utility through discussion of CancerTYPE ID, a 92-gene expression-based assay for molecular classification of tumors. In particular, evidentiary requirements of analytical validity, clinical validity, clinical utility and health effectiveness will be presented along with highlighting how the clinical value story is organized for various healthcare stakeholders.

The discussion will examine the engagement of a broad spectrum of stakeholders, to generate, gather and interpret real world evidence to inform the development and implementation of payer policies and support the translation of molecular medicine products into practice. It will review how to gain meaningful diagnostic insights and provide clinical and economic benefits to patients, healthcare providers, and payers including real-world clinical research to generate evidentiary standards to inform coverage decisions, creation of actionable insights from actual spend & reimbursement trends, and implementation of personalized medicine interventions into practice, where appropriate, toward better managing outcomes and costs.

3:05 PANEL DISCUSSION
Moderator: Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors

Additional Panelists:
Elaine K. Jeter, M.D., Medical Director, Palmetto GBA
Sheila D. Walcoff, Esq., Founding Principal, Goldbug Strategies LLC and Counsel for the Coalition for 21st Century Medicine

4:00 Close of Commercialization of Molecular Diagnostics Conference

Moderator:
Andrew Fish, J.D., Executive Director, AdvaMed Dx

Panelists:
Meeting Informatics Challenges in a Genomic World
M. Michael Barnarda, Ph.D., Associate Professor of Human Genetics; Director, Center for Computational Genetics, GSPH; Associate Director, Center for Simulation and Modeling, University of Pittsburgh

In particular, evidentiary requirements of analytical validity, clinical validity, clinical utility and health effectiveness will be presented along with highlighting how the clinical value story is organized for various healthcare stakeholders.

In the era towards individualizing patient care, the changing landscape of molecular diagnostics presents many challenges to enabling clinical adoption and applicability of high complexity tests. This presentation will discuss the importance of accurate tumor classification in current paradigms of evidence-based patient management, overview perspectives and propose a framework for developing clinical utility through discussion of CancerTYPE ID, a 92-gene expression-based assay for molecular classification of tumors. In particular, evidentiary requirements of analytical validity, clinical validity, clinical utility and health effectiveness will be presented along with highlighting how the clinical value story is organized for various healthcare stakeholders.

The discussion will examine the engagement of a broad spectrum of stakeholders, to generate, gather and interpret real world evidence to inform the development and implementation of payer policies and support the translation of molecular medicine products into practice. It will review how to gain meaningful diagnostic insights and provide clinical and economic benefits to patients, healthcare providers, and payers including real-world clinical research to generate evidentiary standards to inform coverage decisions, creation of actionable insights from actual spend & reimbursement trends, and implementation of personalized medicine interventions into practice, where appropriate, toward better managing outcomes and costs.

3:05 PANEL DISCUSSION
Moderator: Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors

Additional Panelists:
Elaine K. Jeter, M.D., Medical Director, Palmetto GBA
Sheila D. Walcoff, Esq., Founding Principal, Goldbug Strategies LLC and Counsel for the Coalition for 21st Century Medicine

4:00 Close of Commercialization of Molecular Diagnostics Conference

Moderator:
Andrew Fish, J.D., Executive Director, AdvaMed Dx

Panelists:
Meeting Informatics Challenges in a Genomic World
M. Michael Barnarda, Ph.D., Associate Professor of Human Genetics; Director, Center for Computational Genetics, GSPH; Associate Director, Center for Simulation and Modeling, University of Pittsburgh

In particular, evidentiary requirements of analytical validity, clinical validity, clinical utility and health effectiveness will be presented along with highlighting how the clinical value story is organized for various healthcare stakeholders.

In the era towards individualizing patient care, the changing landscape of molecular diagnostics presents many challenges to enabling clinical adoption and applicability of high complexity tests. This presentation will discuss the importance of accurate tumor classification in current paradigms of evidence-based patient management, overview perspectives and propose a framework for developing clinical utility through discussion of CancerTYPE ID, a 92-gene expression-based assay for molecular classification of tumors. In particular, evidentiary requirements of analytical validity, clinical validity, clinical utility and health effectiveness will be presented along with highlighting how the clinical value story is organized for various healthcare stakeholders.

The discussion will examine the engagement of a broad spectrum of stakeholders, to generate, gather and interpret real world evidence to inform the development and implementation of payer policies and support the translation of molecular medicine products into practice. It will review how to gain meaningful diagnostic insights and provide clinical and economic benefits to patients, healthcare providers, and payers including real-world clinical research to generate evidentiary standards to inform coverage decisions, creation of actionable insights from actual spend & reimbursement trends, and implementation of personalized medicine interventions into practice, where appropriate, toward better managing outcomes and costs.

3:05 PANEL DISCUSSION
Moderator: Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors

Additional Panelists:
Elaine K. Jeter, M.D., Medical Director, Palmetto GBA
Sheila D. Walcoff, Esq., Founding Principal, Goldbug Strategies LLC and Counsel for the Coalition for 21st Century Medicine

4:00 Close of Commercialization of Molecular Diagnostics Conference

Moderator:
Andrew Fish, J.D., Executive Director, AdvaMed Dx

Panelists:
Meeting Informatics Challenges in a Genomic World
M. Michael Barnarda, Ph.D., Associate Professor of Human Genetics; Director, Center for Computational Genetics, GSPH; Associate Director, Center for Simulation and Modeling, University of Pittsburgh

In particular, evidentiary requirements of analytical validity, clinical validity, clinical utility and health effectiveness will be presented along with highlighting how the clinical value story is organized for various healthcare stakeholders.

In the era towards individualizing patient care, the changing landscape of molecular diagnostics presents many challenges to enabling clinical adoption and applicability of high complexity tests. This presentation will discuss the importance of accurate tumor classification in current paradigms of evidence-based patient management, overview perspectives and propose a framework for developing clinical utility through discussion of CancerTYPE ID, a 92-gene expression-based assay for molecular classification of tumors. In particular, evidentiary requirements of analytical validity, clinical validity, clinical utility and health effectiveness will be presented along with highlighting how the clinical value story is organized for various healthcare stakeholders.

The discussion will examine the engagement of a broad spectrum of stakeholders, to generate, gather and interpret real world evidence to inform the development and implementation of payer policies and support the translation of molecular medicine products into practice. It will review how to gain meaningful diagnostic insights and provide clinical and economic benefits to patients, healthcare providers, and payers including real-world clinical research to generate evidentiary standards to inform coverage decisions, creation of actionable insights from actual spend & reimbursement trends, and implementation of personalized medicine interventions into practice, where appropriate, toward better managing outcomes and costs.

3:05 PANEL DISCUSSION
Moderator: Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors

Additional Panelists:
Elaine K. Jeter, M.D., Medical Director, Palmetto GBA
Sheila D. Walcoff, Esq., Founding Principal, Goldbug Strategies LLC and Counsel for the Coalition for 21st Century Medicine

4:00 Close of Commercialization of Molecular Diagnostics Conference

Moderator:
Andrew Fish, J.D., Executive Director, AdvaMed Dx

Panelists:
Meeting Informatics Challenges in a Genomic World
M. Michael Barnarda, Ph.D., Associate Professor of Human Genetics; Director, Center for Computational Genetics, GSPH; Associate Director, Center for Simulation and Modeling, University of Pittsburgh

In particular, evidentiary requirements of analytical validity, clinical validity, clinical utility and health effectiveness will be presented along with highlighting how the clinical value story is organized for various healthcare stakeholders.

In the era towards individualizing patient care, the changing landscape of molecular diagnostics presents many challenges to enabling clinical adoption and applicability of high complexity tests. This presentation will discuss the importance of accurate tumor classification in current paradigms of evidence-based patient management, overview perspectives and propose a framework for developing clinical utility through discussion of CancerTYPE ID, a 92-gene expression-based assay for molecular classification of tumors. In particular, evidentiary requirements of analytical validity, clinical validity, clinical utility and health effectiveness will be presented along with highlighting how the clinical value story is organized for various healthcare stakeholders.

The discussion will examine the engagement of a broad spectrum of stakeholders, to generate, gather and interpret real world evidence to inform the development and implementation of payer policies and support the translation of molecular medicine products into practice. It will review how to gain meaningful diagnostic insights and provide clinical and economic benefits to patients, healthcare providers, and payers including real-world clinical research to generate evidentiary standards to inform coverage decisions, creation of actionable insights from actual spend & reimbursement trends, and implementation of personalized medicine interventions into practice, where appropriate, toward better managing outcomes and costs.

3:05 PANEL DISCUSSION
Moderator: Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors

Additional Panelists:
Elaine K. Jeter, M.D., Medical Director, Palmetto GBA
Sheila D. Walcoff, Esq., Founding Principal, Goldbug Strategies LLC and Counsel for the Coalition for 21st Century Medicine

4:00 Close of Commercialization of Molecular Diagnostics Conference
SPONSOR & EXHIBITOR OPPORTUNITIES

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space and branding, as well as the use of the pre and post show delegate lists. Sponsorship allows you to achieve your objectives before, during, and long after the event. Any sponsorship can be customized to meet your company’s needs and budget. Signing on earlier will allow you to maximize exposure to hard-to-reach decision makers.

**Agenda Presentations**
Showcase your solutions to a guaranteed, highly-targeted audience. Package includes a 15 or 30-minute podium presentation within the scientific agenda, exhibit space, on-site branding and access to cooperative marketing efforts by CHI.

**Breakfast & Luncheon Presentations**
Opportunity includes a 30-minute podium presentation. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. A limited number of presentations are available for sponsorship and they will sell out quickly. Sign on early to secure your talk!

**Invitation-Only VIP Dinner/Hospitality Suite**
Sponsors will hand-pick their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects. Evening will be customized according to sponsor’s objectives (i.e. purely social, focus group, reception style or plated dinner, plated dinner with specific conversation focus).

**CHI Lead Generation**
CHI can help you with lead generation throughout the year. Our internal database includes over 800,000 prospects in the life sciences. By leveraging the database and mining for your specific requirements, we can produce multiple custom projects which will deliver your prospective buyers:

- Web Symposia
- Podcasts
- White Papers
- Custom Market Research Surveys
- And More!

**Exhibit Information**
Exhibitors will enjoy facilitated networking opportunities with qualified decision makers at the Next Generation Diagnostics Summit, making it the perfect platform to launch a new product, collect feedback and generate new leads. Exhibit space sells out quickly, so reserve yours today!

Additional networking & promotional opportunities are available!

**For additional information, please contact:**
Joseph Vacca
Manager, Business Development
781-972-5431 | jvacca@healthtech.com

**2011 Sponsors & Exhibitors**
Advanced Cell Diagnostics  KMC Systems  ResearchDx, LLC
ArcticZymes  Luminex  Signal Genetics
Asuragen  OriGene  SurModics
BD Diagnostics  Pathogenica  Theranostics Health
Biosearch Technologies  PrimerDX  TwistDx Limited
Boston Healthcare Associates  Promise Advanced Proteomics  Veridex
Cureline, Inc.  QIAGEN  Wi, Inc.
Exosome Diagnostics  Randox Labs
Hologic  Renishaw Diagnostics

“...The meeting was very worthwhile. Engaged audience, interesting presentations, well attended by decision makers and leaders in the industry. We enjoyed exciting discussions which gave us perspective on where our technology fits in the market.”

- VP of Business Development, Exosome Diagnostics

Reserve your exhibit space by May 18th & SAVE $300
If you are unable to attend but would like to purchase the Next Generation Dx Summit CD for $750 (plus shipping), please visit NextGenerationDx.com. Massachusetts delivery will include sales tax.

How to Register: NextGenerationDx.com reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please refer to the Registration Code below:

**Pricing and Registration Information**

**PARTNERING FORUM**

(Includes access to Partnering Forum only)

- Emerging Diagnostic Partnering and Investment Forum
  - Non-Attendee: $1395
  - Conference Attendee: $995

**CONFERENCE PRICING**

**SUMMIT PRICING — BEST VALUE!**

(Includes access to 2 conferences, excludes short courses)

- Commercial: $2395
- Academic, Government, Hospital-affiliated: $1045

**SINGLE CONFERENCE**

(Indicates access to 1 conference, excludes short courses)

- Registrations after July 27, 2012, and on-site
  - $1775
  - $725

**August 21-22**

- Enabling Point-of-Care Diagnostics
- Emerging Molecular Markers of Cancer
- Mass Spectrometry in Diagnostics of Infectious Disease
- Regulatory Compliance in Drug-Diagnostic Co-Development

**August 22-23**

- Molecular Diagnostics for Infectious Disease
- Companion Diagnostics
- Commercialization of Molecular Diagnostics

**SHORT COURSES**

(Indicates access to short courses only)

- One short course
  - Commercial: $695
  - Academic, Government, Hospital-affiliated: $395
- Two short courses
  - $995
  - $695
- Three short courses
  - $1195
  - $795

**CONFERENCE DISCOUNTS**

**Poster Submission-Discount ($50 Off)**

Poster abstracts are due by July 20, 2012. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com.

CHI reserves the right to publish your poster title and abstract in various marketing materials and products.

**REGISTER 3 - 4th IS FREE:** Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply.

Additional discounts are available for multiple attendees from the same organization. For more information on group rates contact David Cunningham at +1-781-972-5472

**How to Register:** NextGenerationDx.com

**ADDITONAL REGISTRATION DETAILS**

Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.

**Handicapped Equal Access:** In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

To view our Substitutions/Cancellations Policy, go to http://www.healthtech.com/regdetails

Video and or audio recording of any kind is prohibited onsite at all CHI events.

If you are unable to attend but would like to purchase the Next Generation Dx Summit CD for $750 (plus shipping), please visit NextGenerationDx.com. Massachusetts delivery will include sales tax.

Please use keycode 1280 F when registering!